Literature DB >> 2574646

The half-life of exogenous growth hormone after suppression of endogenous growth hormone secretion with somatostatin.

P C Hindmarsh1, D R Matthews, C E Brain, P J Pringle, L di Silvio, A B Kurtz, C G Brook.   

Abstract

We have estimated the half-life of serum growth hormone (GH) in six subjects on 14 occasions following an intravenous bolus injection of either 50 or 500 mU of biosynthetic human growth hormone (B-hGH) while endogenous GH secretion was suppressed by a continuous infusion of somatostatin. The disappearance curve of serum GH was mono-exponential and the mean half-life was 8.9 min (SD 1.5). This is less than previously reported and has important implications for the performance of GH profiles, which should be performed with 10-15 min sampling intervals, and the calculation of pituitary GH secretion rates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574646     DOI: 10.1111/j.1365-2265.1989.tb00444.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

Review 1.  The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors:  R J Wills; B L Ferraiolo
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.

Authors:  Iftekhar Mahmood; Martin D Green
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Motivations and methods for analyzing pulsatile hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Steven M Pincus
Journal:  Endocr Rev       Date:  2008-10-21       Impact factor: 19.871

4.  Repetitive stimulation of the pituitary with growth-hormone-releasing hormone alters the proportion of 22 and 20 kilodalton human-growth hormone released.

Authors:  Emma A Webb; P Jane Pringle; Iain C A F Robinson; Peter C Hindmarsh
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-09

5.  Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release.

Authors:  M L Hartman; S M Pincus; M L Johnson; D H Matthews; L M Faunt; M L Vance; M O Thorner; J D Veldhuis
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

6.  Physiological levels of growth hormone fail to suppress growth hormone releasing hormone (1-29) NH2-stimulated growth hormone secretion in man.

Authors:  C Brain; D N Thakrar; P C Hindmarsh; C G Brook
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

7.  Treatment of Growth Hormone Deficiency via Daily Intravascular Injections in a Child with Bleeding Disorder.

Authors:  Emir Tas; Serife E Uzun; Vildan Tas; Juan D Mejia-Otero
Journal:  Case Rep Endocrinol       Date:  2021-06-17

8.  Effects of a single dose of N-Acetyl-5-methoxytryptamine (Melatonin) and resistance exercise on the growth hormone/IGF-1 axis in young males and females.

Authors:  Erika Nassar; Chris Mulligan; Lem Taylor; Chad Kerksick; Melyn Galbreath; Mike Greenwood; Richard Kreider; Darryn S Willoughby
Journal:  J Int Soc Sports Nutr       Date:  2007-10-23       Impact factor: 5.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.